SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Li Zhang
Sun Yat-sen University Cancer Center (SYSUCC)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
- Sun Yat-Sen University Cancer Center (sysucc)
Guangzhou, Guangdong, China
- the Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
- the Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
- Shandong Cancer Hospital
Jinan, Shandong, China
- Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Dec 2021
- Primary completion
- 31 Dec 2025
- Completion
- 31 Dec 2025
- Last update posted
- 26 Sept 2025
- Registered enrollment
- 69
- Registry id
- NCT05020457
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.